论文部分内容阅读
目的探讨亲属活体肾造血干细胞联合移植诱导免疫耐受的可行性及安全性。方法对3例女性尿毒症患者进行亲属活体肾造血干细胞联合移植(观察组);同期接受亲属活体肾移植的5例女性尿毒症患者作为对照组。供体均为男性。采用PCR-SRY方法进行嵌合体检测。测定受体淋巴细胞亚群,随访观察肾造血干细胞联合移植的并发症和临床移植效果并与对照组进行比较分析。结果观察组嵌合体阳性率100%,对照组60%;观察组肾移植受者临床效果良好,呈现免疫低反应和免疫抑制趋势。结论亲属活体肾造血干细胞联合移植是一种可行的诱导免疫耐受的方法,可以诱导产生临床肾移植的免疫低反应。
Objective To investigate the feasibility and safety of co-transplantation of renal allogeneic hematopoietic stem cells to induce immune tolerance. Methods Three female patients with uremia were treated with living donor renal allogeneic hematopoietic stem cell transplantation (observation group). Five female uremic patients receiving relative living donor kidney transplantation were selected as the control group. Donors are men. PCR-SRY method for chimera detection. The recipient lymphocyte subsets were determined. The complication and clinical effect of combined transplantation of renal allogeneic hematopoietic stem cells were observed and compared with the control group. Results The positive rate of chimerism in the observation group was 100% and that in the control group was 60%. The renal transplant recipients in the observation group had good clinical effect and showed the immunosuppression and immunosuppression tendency. Conclusions Relative live donor renal allogeneic hematopoietic stem cell transplantation is a feasible method of inducing immune tolerance, which can induce immune hyporesponse of clinical renal transplantation.